Methods

CT scans from pts with EGFR mutation-positive NSCLC were retrospectively collected post-study and reviewed by a third party (double read with adjudication paradigm with predefined assessment criteria for RECIST progression) independently of AstraZeneca. Reviewers were blinded to investigational site scan results and treatment assignment.